MIF Deficiency Does Not Alter Glucose Homeostasis or Adipose Tissue Inflammatory Cell Infiltrates during Diet-Induced Obesity

Sarah J. Conine and Janet V. Cross

Objective: Circulating macrophage migration inhibitory factor (MIF) levels have been shown to positively correlate with body mass index (BMI) in humans. Our objective in this study was to determine the effects of MIF deficiency in a model of high-fat diet-induced obesity.

Design and Methods: MIF wild type (MIF WT) and MIF deficient (MIF–/–) C57Bl/6J mice were fed a high-fat diet (HFD) for up to 15 weeks. Weight and metabolic responses were measured over the course of the disease. Immune cell infiltrates in visceral and subcutaneous adipose tissue were examined by flow cytometry.

Results: There was no difference in weight gain or adipose tissue mass in MIF–/– mice compared to MIF WT mice. Both groups fed HFD developed glucose intolerance at the same rate and had similar elevations in fasted blood insulin. MDSC abundance was evaluated and showed no MIF-dependent differences. Macrophages were elevated in the visceral adipose tissue of obese mice, but there was no difference between the two groups.

Conclusions: While HFD feeding induced obesity with the expected perturbations in glucose homeostasis and adipose tissue inflammation, the presence or absence of MIF had no effect on any parameter examined.

Obesity (2014) 22, 418–425. doi:10.1002/oby.20555

Introduction

Obesity is a multifactorial disease affecting numerous tissues and physiological processes (1). Metabolic dysregulation during obesity leads to problems such as glucose intolerance, insulin resistance, and Type 2 diabetes (2,3). Chronic inflammation also arises as a result of excessive weight gain (4,5). Adipocytes that are damaged or stressed by high lipid intake produce signals that reprogram the inflammatory response from a maintenance Th2/M2 response to a proinflammatory Th1/M1 response (6-8). While not completely understood, these immunological changes are thought to contribute to the damage of adipocytes that aids in metabolic disruption resulting in problems such as insulin resistance (9).

Researchers and clinicians alike have become very interested in the potential roles of macrophage migration inhibitory factor (MIF) in the development of obesity. Human studies have demonstrated a strong positive correlation between body mass index (BMI) and circulating MIF levels (10,11). It has also been shown that MIF mRNA levels in the visceral white adipose tissue (vWAT) positively correlate with percentage of body fat (12). Mice that are deficient in MIF are protected from the onset of glucose intolerance in the context of a pro-atherogenic model (LDLR–/–) (13). These data have led to speculation that MIF contributes to some of the complications of obesity and that inhibition of MIF may provide a therapeutic approach for some of the co-morbidities of the disease (14,15).

MIF is a widely expressed protein that participates in pathways significant for both metabolism and regulation of the immune system. MIF promotes insulin secretion in the pancreas (16). The absence of MIF protects beta cells from fatty acid-induced apoptosis and helps preserve beta cell function (16,17). MIF deficient mice have a more rapid onset of age-induced glucose intolerance, although they exhibit no differences in glucose metabolism compared to wild type (WT) mice throughout most of their lives (18). MIF deficient mice are also less susceptible to streptozotocin (STZ)-induced diabetes, in that multiple low doses of STZ failed to elevate blood glucose in MIF–/– mice to the same degree as MIF WT (19,20).

MIF has been shown to regulate several distinct inflammatory processes (21). The protein was originally identified and named for its...
Thorough studies of high-fat diet (HFD)-fed MIF WT and MIF–/– mice demonstrated that mice that also lacked MIF (LDLR+/−-MIF+/−) exhibited fewer macrophages infiltrating into epididymal adipose tissue (13). In the 4T1 breast cancer model, our group has shown that tumor-derived MIF positively regulates the abundance of monocyteic myeloid-derived suppressor cells (MDSCs) in the tumor (24). MIF has also been shown to promote alternative activation of tumor-associated macrophages (TAMs) and suppressive function of both TAMs and MDSCs (25).

MDSCs are known to suppress T cells and, to some extent NK cells, and are best characterized in the context of cancer (26,27). MDSCs are under studied in obesity; however, Xia et al. (28) have demonstrated that MDSCs are increased during obesity and that they contribute to protection from both inflammation and development of insulin resistance that result from obesity. The monocytic subtype (mMDSC) is known to be more suppressive of T cells than the granulocytic population (gMDSC), and can also be induced to differentiate into macrophages under certain conditions (26,29,30). To our knowledge, the potential roles of the two recognized MDSC subsets, granulocytic MDSCs and monocytic MDSCs, have not been explored in any model of obesity.

The clinical data from obesity studies and the potential importance of MIF in both metabolism and immune cell infiltration led us to explore the effects of MIF deletion in the context of diet-induced obesity. Based on our observations in the 4T1 tumor model, we hypothesized that MIF would promote the prevalence of mMDSCs in obese vWAT and that this would contribute to the proinflammatory environment that promotes diet-induced glucose intolerance. Thorough studies of high-fat diet (HFD)-fed MIF WT and MIF–/– mice demonstrate that the absence of MIF does not alter obesity, inflammatory cell accumulation in vWAT, or the development of HFD-induced glucose intolerance.

**Methods**

**Animals**

Heterozygous MIF+/− Balb/c mice (31) were obtained from cryopreserved stocks maintained at Jackson Labs (Bar Harbor, ME). Mice were backcrossed onto C57Bl/6 using speed congenic microsatellite marker screening to allow completion of the backcross in six generations. Male 6- to 8-week old homozygous MIF WT and MIF-deficient (MIF−/−) C57Bl/6 mice were fed either normal chow (Harlan 7012) or 60% fat/kcal diet (HFD, Research Diets, New Brunswick, NJ) for up to 15 weeks. Mass of the animals was monitored over the course of HFD feeding. All experiments were conducted in accordance with guidelines of the University of Virginia Animal Care and Use Committee.

**Isolation of stromal-vascular fraction**

At the time of harvest, mice were perfused immediately postmortem with PBS and visceral and subcutaneous adipose depots collected. Weights of these adipose depots were recorded, and lymph nodes were excised from the sWAT prior to further processing. Adipose tissue was finely minced in a solution of Krebs–Ringer–HEPES (KRH) Buffer plus 2.5% BSA and then digested with 2 mg of collagenase I ( Worthington Biochemical, Lakewood, NJ) per gram of fat at 37°C for 45–60 minutes.

Tissue fragments were removed from the digests by straining through a 400 μm pore mesh (Sefar, Buffalo, NY). The stromal-vascular cell fraction (SVF) was pelleted by centrifugation at 400g for 10 minutes at 4°C. Floating cells (adipocytes) were removed by aspirating the supernatant and the SVF pellet was washed again before filtration through a 70 μm pore filter to obtain a final single cell suspension.

**Flow cytometry**

Flow cytometry was used to immunophenotype the isolated SVF with the following stains/antibodies: LIVE/DEAD Fixable Red Dead Stain (Invitrogen), CD45 PerCP (clone 30-F11, BD Biosciences), CD11b Pacific Blue (M1/70.15, Invitrogen), F4/80 APC-eFluor780 (BM8, eBioscience), Ly6C APC (HK1.4, BioLegend) and Ly6G FITC (1A8, BioLegend). Single cells were gated by forward and side scatter followed by gating for live, CD45+, CD11b+ to identify the myeloid cells. Further gating of Ly6C and Ly6G was utilized to discern mMDSC and gMDSC subtypes, while F480+ cells were defined as macrophages. A representative gating strategy is provided in Supporting Information Figure 3. CountBright counting beads (Invitrogen) were included in all samples to allow for determination of absolute cell numbers. Flow cytometry was performed using the CyaN ADP LX 9 Color Flow Cytometer (Beckman Coulter). Data analysis was performed using FlowJo software (Tree Star, Ashland, OR) and gates were set based on fluorescence minus one (FMO) controls.

**Liver histology**

Livers from mice that had been fed a HFD for 15 weeks were harvested following perfusion. The tissue was fixed for 24 hours in formalin, embedded in paraffin, sectioned, and stained with H&E.

**Measurement of blood glucose and blood insulin levels**

To obtain random-fed blood samples, mice that had been on HFD for 12 weeks were separated into individual cages the night before blood collection and provided food and water *ad libitum*. The following morning (15–16 hours later) 2–3 mm of the tail of each mouse was amputated, and blood was collected to measure blood glucose using a glucose meter (Accu-Chek Advantage, Roche Diagnostics, Indianapolis, IN), following which 25–40 μl of blood was drawn into a heparinized capillary tube. Plasma was isolated by centrifugation at 1600g for 10 minutes at 4°C. Samples were stored at −20°C for batched assay.

For blood collection from fasted mice, animals fed a HFD for 11 weeks were separated into individual Sani-Chip (Harlan) bedding cages with water, but no food, and fasted for 15–16 hours (overnight). Blood samples and glucose measurements were taken as described above, except that 50–75 μl of blood was required from fasted mice. Plasma was isolated as described above and stored at −20°C.

Blood insulin levels in both fasted and random-fed mice were measured using an Ultrasensitive Insulin ELISA kit (ALPCO, Salem, NH) per manufacturer’s instructions, except that detection was enhanced by substituting Amplex Red in phosphate buffer in place of the substrate provided (32).

**Intrapertioneal glucose tolerance tests**

Mice were weighed and separated into individual Sani-Chip cages to fast for 15–16 hours with water, but no food. Baseline blood glucose
measurements were taken using a glucose meter and blood from the tail of each mouse. Immediately after the baseline reading, each mouse was given an intraperitoneal (IP) injection of 1.4 g/kg of D-glucose. Subsequent blood glucose readings were taken at 15, 30, 45, 60, 90, and 120 minutes post-injection. Data were averaged and graphed as blood glucose as a function of time.

Statistics
Data are displayed as mean ± SEM and were analyzed using one-way ANOVA, two-way ANOVA, or unpaired two-tailed Student’s t-test as indicated in the figure legends. Significance was defined as $P < 0.05$ and is indicated by a single asterisk in the figures.

Results
MIF deficiency does not impact weight gain during diet-induced obesity
The observed correlations between MIF levels and obesity in both humans and other animal models prompted us to determine if the absence of MIF in a mouse model of diet-induced obesity would result in changes in weight gain over the course of the disease (10,11,17,33). MIF WT and MIF$^{-/-}$ C57Bl/6 mice were placed on HFD for 15 weeks. Total weight was tracked throughout the course of HFD feeding. We found that HFD-fed mice gained significantly more weight than their chow-fed controls; however, there was no difference in weight gain between the MIF WT and MIF$^{-/-}$ groups (Figure 1A).

It is possible that while there was no difference in the overall weight gain between MIF WT and MIF$^{-/-}$ mice, these two groups might vary in the distribution of increased fat mass between the primary adipose tissue depots. Mice were sacrificed after 15 weeks on either HFD or normal chow diet for quantification of visceral adipose tissue (vWAT) and subcutaneous adipose tissue (sWAT) masses. While both MIF WT and MIF$^{-/-}$ mice fed HFD had significantly larger fat depots compared to their chow-fed counterparts, both obese WT and obese MIF$^{-/-}$ animals gained sWAT and vWAT masses equivalently (Figure 1B and C).

To determine if MIF could be important in the early stages of obesity, we placed 4-week old mice on HFD for either 1 or 4 weeks. We found no difference between the weights of MIF WT and MIF$^{-/-}$ mice at these stages, nor was there any difference in vWAT mass in the MIF WT and MIF$^{-/-}$ groups at 8 weeks of HFD feeding (Figure 1B and C).
mass (Supporting Information Figure 1A and B). Taken together, these data suggest that MIF does not play a direct role in weight gain or distribution of expanding adipose tissue mass during the development of obesity in this model.

**MIF does not influence MDSC or macrophage infiltration into vWAT during weight gain**

The inflammation that results from increased weight gain has pleiotropic effects on the organism, but is still poorly understood. MIF has been shown to be important in the recruitment of immune cells such as macrophages, neutrophils, and MDSCs in models of cancer and arthritis (23,24,34). Knowing that MIF is involved in the regulation of many inflammatory processes in various disease settings, we set out to determine if MIF influences MDSC or macrophage prevalence in obese adipose tissue.

vWAT and sWAT were harvested from MIF WT and MIF−/− mice that had been fed a HFD for 15 weeks. The SVF from these depots was isolated and stained for monocytic MDSCs (Ly6Chi, Ly6Glo), granulocytic MDSCs (Ly6Ghi, Ly6Clo), and macrophages (F4/80+). Neither diet nor genotype influenced mMDSC or gMDSC prevalence in the vWAT (Figure 2A, Supporting Information Figure 2A), although the obese vWAT showed an increase in total MDSCs compared to chow controls (Supporting Information Figure 2E). As expected, we observed an increase in F4/80+ macrophages in the vWAT of HFD-fed mice; however, the absence of MIF did not lead to any change in the macrophage population as compared to the WT HFD group (Figure 2B, Supporting Information Figure 2C). No differences in any of the three immune cell populations were found between MIF WT and MIF−/− mice on HFD in the sWAT (Figure 2B and D, Supporting Information Figure 2B and D). Interestingly, MIF−/− mice on HFD demonstrated a statistically significant increase in the percentage of infiltrating F4/80+ cells compared to the chow controls. This difference was not seen between the MIF WT HFD and MIF WT chow mice (Figure 2D). Immunophenotyping of the visceral fat depots of mice that had been fed HFD for only 1 or 4 weeks also demonstrated no significant differences in MDSC infiltration at earlier time points (Supporting Information Figure 1C and D). These data demonstrate that the absence of MIF does not lead to differences in the abundance of MDSCs or macrophages in obese adipose tissue.

Knowing that excess lipids that are not successfully stored in the adipose depots are often deposited in the liver (35), we sought to determine if MIF deficiency might alter lipid deposition in the liver. We harvested livers from mice that had been on HFD for 15 weeks and stained sections with H&E. There was a marked increase in

![Figure 2](https://www.obesityjournal.org/volume-22/number-2/february-2014/421)

**FIGURE 2** MIF deficiency does not affect MDSC or macrophage abundance during diet-induced obesity. (A–D) The SVF was purified from the vWAT and sWAT of WT and MIF−/− mice that had been fed either chow or HFD for 15 weeks. Cells were stained with a live/dead marker along with fluorescent antibodies for the cell surface markers CD45, CD11b, Ly6C, Ly6G, and F4/80. Among the live, CD45+, CD11b+ cell populations, no significant differences were seen in the gMDSC (Ly6Ghi, Ly6Clo) or mMDSC (Ly6Chi, Ly6Glo) populations in the vWAT (A) or sWAT (B) of MIF WT versus MIF−/− mice. Macrophages (F4/80+) were elevated in the vWAT (C) of obese mice (P<0.05), however, no significant differences were seen in the vWAT (C) or sWAT (D) between WT and MIF−/− mice on HFD. N = 4–13 per group. Statistical significance was tested using one- or two-way ANOVA. Asterisks indicate differences from chow controls.
lipid accumulation in the livers of all obese animals; however, we saw no difference because of the presence or absence of MIF (Figure 3).

**MIF deficiency does not influence the development of glucose intolerance**

Given the apparent absence of differences in weight gain and immune cell populations in the adipose tissue, we wanted to determine if there was a difference in the metabolic responses of MIF WT and MIF−/− mice after an extended period on HFD. As a functional readout of glucose metabolism, IP glucose tolerance tests (IPGTTs) were performed on cohorts of mice that had been on a HFD for 5, 8, or 12 weeks. As expected, a delay in the response to glucose challenge was observed in obese mice at all three time points. However, there was no difference in glucose response between the MIF WT and MIF−/− mice, suggesting that the absence of MIF neither inhibits nor promotes the development of glucose intolerance (Figure 4A–C).

Differences in insulin secretion could account for similar IPGTT curves that mask an underlying metabolic perturbation. Therefore, we measured both random-fed and fasted blood insulin levels in these mice. HFD groups showed slight elevations in their blood insulin levels in both random-fed and fasted conditions. However, there was no significant difference in insulin levels between the obese MIF WT and MIF−/− groups (Figure 5B and D). Random-fed and fasted blood glucose concentrations were monitored concurrently with insulin levels and while there was a slight elevation of fasted HFD glucose levels in obese mice compared to chow-fed controls, again, there was no indication that the absence of MIF had any effect (Figure 5A and C). Taken together, these data suggest that the presence or absence of MIF alone is not sufficient to change the development of insulin resistance during diet-induced obesity.

**Discussion**

We have shown that in a mouse model of diet-induced obesity, the absence of MIF does not impact weight gain or adipose tissue mass. The human data showing correlations between BMI and MIF (10,11) might lead one to expect that lack of MIF would result in decreased weight gain compared to WT. Given our data, we believe that the increase in MIF seen during obesity may be an effect, rather than a cause of weight gain and increased adiposity. For example, it is known that preadipocytes increase MIF secretion during the

![Figure 3](https://example.com/figure3.png)

**Figure 3** Lipid deposition is the same in the livers of obese WT and MIF−/− mice. Livers from 15-week chow-fed and HFD-fed WT and MIF−/− mice were processed for histologic sections and stained with H&E. Chow-fed livers appear normal (A and B) compared to HFD-fed livers (C and D), which have marked lipid deposition. No MIF-dependent differences were observed in any condition tested. 8× magnification. [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
Obesity results in an increased rate of preadipocyte differentiation to adipose tissue (36). Obesity results in an increased rate of preadipocyte differentiation to adipose tissue (36). Obesity results in an increased rate of preadipocyte differentiation to adipose tissue (36). Obesity results in an increased rate of preadipocyte differentiation to adipose tissue (36). Obesity results in an increased rate of preadipocyte differentiation to adipose tissue (36). Obesity results in an increased rate of preadipocyte differentiation to adipose tissue (36). Obesity results in an increased rate of preadipocyte differentiation to adipose tissue (36). Obesity results in an increased rate of preadipocyte differentiation to adipose tissue (36). Obesity results in an increased rate of preadipocyte differentiation to adipose tissue (36). Obesity results in an increased rate of preadipocyte differentiation to adipose tissue (36).

In this study, we have demonstrated that MIF does not impact the abundance of mMDSCs, gMDSCs, or F4/80+ macrophage populations in the vWAT. These data do not support our initial hypothesis that MIF expression would positively regulate the prevalence of mMDSCs in adipose tissue during obesity, as we have shown in a breast cancer model (24). We did see the expected increase in macrophages and total MDSCs due to the onset of obesity (Figure 2, Supporting Information Figure 2); however, we did not observe any MIF-dependent changes in myeloid cell infiltration into vWAT during obesity. While our study carefully examined the number of cells infiltrating into the fat, we did not address the function of these cells. Therefore, it remains possible that MIF could exert some effect on the role that MDSCs or macrophages play once they enter into the vWAT. In particular, it is possible that MIF may influence the relative abundance of M1 versus M2 macrophages within the adipose tissue. The M1 versus M2 phenotype has been shown to play a role in the pathogenesis of obesity (38), however, even if there is a MIF-dependent alteration in MDSC and/or macrophage function, that difference does not manifest in any changes in weight gain or in the metabolic effects of glucose intolerance as obesity develops.

Others have shown that MIF is a positive regulator of insulin secretion from pancreatic islets (16). It has also been demonstrated that MIF deficiency protects pancreatic islets from fatty acid-induced apoptosis in vitro (17). These studies are compatible with our hypothesis that MIF−/− mice fed a HFD would develop glucose intolerance at a slower rate than obese WT mice. Instead, we observed that both groups develop similar glucose intolerance and increased insulin levels on HFD regardless of MIF expression. This suggests that MIF is not a key regulator of the damage that leads to obesity-related disruption of glucose homeostasis in vivo and therefore is not a promising therapeutic target for modulation of conditions such as Type 2 diabetes. It is possible that we did not see the predicted metabolic changes in MIF−/− mice because of compensatory pathways that could make up for MIF deficiency or MIF overexpression.

The role of MIF in the development of glucose intolerance has been studied in the context of an atherogenic mouse strain (LDLR−/−). In this model, MIF deficient LDLR−/− mice fed a chow diet developed glucose intolerance at a slower rate than LDLR−/− mice that express MIF. The two groups of mice became obese at the same rate and had no differences in fat mass (13). This study differs from ours in that the effect of MIF deficiency was examined on an atherosclerosis prone background (LDLR−/−) and the composition of the diets was not the same. Either of these factors could result in alterations in both the metabolic and immune responses of the mice. Based on our results, we would contend that while MIF deficiency is protective in the context of genetic predisposition for atherosclerosis, it does not exert an effect in a HFD model of obesity.

Serre-Beinier et al. [18] demonstrated that MIF−/− mice develop age-induced glucose intolerance. Their data showed that MIF WT and MIF−/− mice had no significant differences in glucose tolerance at 2 or 4 months of age. The latest time point tested, 12 months, was the only one to show that MIF−/− mice were more glucose intolerant than MIF WT mice. It is possible that our mice would have shown similar changes over time had our study extended as long. In a different model, Harper et al. (39) demonstrated that MIF−/− mice on a C57BL/6J × 129/SvJae background exhibit increased longevity and are significantly smaller when compared to MIF WT controls. This may be a strain-specific difference, as MIF−/− mice on a pure C57BL/6J background are no different in size than their MIF WT litter mate controls (40), though this study did not address longevity. It is important to note that while there are several studies that have
examined the role of MIF in control of various metabolic parameters, none have compared obese MIF WT and MIF−/− animals to assess diet-induced glucose intolerance, and our data clearly point toward MIF expression not being a key factor in the dysregulated glucose homeostasis resulting from diet-induced obesity.

Our study was designed to determine if MIF would be a good therapeutic target for treating obesity-related metabolic and immunologic co-morbidities. There has been much speculation in the literature that controlled regulation of MIF during obesity may benefit patients; however, up until this point no one had investigated the impact of MIF deletion in an animal model of diet-induced obesity. We provide the first report that the absence of MIF alone is not sufficient to alter either glucose homeostasis or the inflammatory changes that accompany HFD-induced obesity. Taken together, our results suggest that MIF inhibition may not be a useful approach for correction of these aspects of obesity-related disease development.

Acknowledgments

The authors gratefully acknowledge the assistance of Joanne Lannigan and the UVA Flow Cytometry Core as well as the Charles River facility at UVA. We would like to thank Dr. Susanna Keller at the UVA Animal and Cell Characterization Core for assistance with the insulin ELISA. We thank Dan Harmon, Dan Heffron, Jennifer Kaplan, Charles Lyons, Kristen Ruby, Kendra Simpson, Dennis Templeton, and Ken Victor for technical assistance. We would also like to acknowledge Thurl Harris, Coleen McNamara, Kendra Simpson, and Dennis Templeton for many helpful discussions.

© 2013 The Obesity Society

References

1. Lumeng CN, Saltiel AR. Inflammatory links between obesity and metabolic disease. J Clin Invest 2011;121:2111-2117.
2. Shoelson SE, Herrero L, Naaz A. Obesity, inflammation, and insulin resistance. *Gastroenterology* 2007;132:2169-2180.

3. Kahn BB, Flier JS. Obesity and insulin resistance. *J Clin Invest* 2000;106:473-481.

4. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. *Science* 1993; 259:87-91.

5. Gregor MF, Hotamisligil GS. Inflammatory mechanisms in obesity. *Annu Rev Immunol* 2011;29:415-445.

6. Kamegami TD, Dixit VD. Immunological complications of obesity. *Nat Immunol* 2012;13:707-712.

7. Harford KA, Reynolds CM, McGillicuddy FC, Roche HM. Fats, inflammation and insulin resistance: insights to the role of macrophage and T-cell accumulation in adipose tissue. *Proc Nutr Soc* 2011;70:408-417.

8. Chatzigeorgiou A, Karalis KP, Bornstein SR, Chavakis T. Lymphocytes in obesity-related adipose tissue inflammation. *Diabetologia* 2012;55:2583-2592.

9. Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease. *Nat Rev Immunol* 2011;11:98-107.

10. Dandona P, Aljada A, Ghanim H, et al. Increased plasma concentration of macrophage migration inhibitory factor (MIF) and MIF mRNA in mononuclear cells in the obese and the suppressive action of metformin. *J Clin Endocrinol Metab* 2004;89:5043-5047.

11. Ghanim H, Aljada A, Hofmeyer D, Syed T, Mohanty P, Dandona P. Circulating mononuclear cells in the obese are in a proinflammatory state. *Circulation* 2004;110:1564-1571.

12. Alvehus M, Burén J, Sjäström M, Goedecke J, Olsson T. The human visceral fat depot has a unique inflammatory profile. *Obesity (Spring)* 2010;18:879-883.

13. Verschuren L, Koosta T, Bernhagen J, et al. MIF deficiency reduces chronic inflammation in white adipose tissue and impairs the development of insulin resistance, glucose intolerance, and associated atherosclerotic disease. *Circ Res* 2009;105:99-107.

14. Finucane OM, Reynolds CM, McGillicuddy FC, Roche HM. Insights into the role of macrophage migration inhibitory factor in obesity and insulin resistance. *Proc Nutr Soc* 2012;71:622-633.

15. Stojanovic I, Saksida T, Stovic-Grujicic S. Beta cell function: the role of macrophage migration factor. *Immunol Lett* 2012;52:81-88.

16. Waeger B, Calandra T, Roduit R, et al. Insulin secretion is regulated by the glucose-dependent production of islet beta cell macrophage migration inhibitory factor. *Proc Natl Acad Sci U S A* 1997;94:4782-4787.

17. Saksida T, Stovic-Grujicic S, Timotijevic G, Sandler S, Stojanovic I. Macrophage migration inhibitory factor deficiency protects pancreatic islets from palmitic acid-induced apoptosis. *Immunol Cell Biol* 2012;90:688-698.

18. Serre-Beinier V, Toso C, Morel P, et al. Macrophage migration inhibitory factor deficiency leads to age-dependent impairment of glucose homeostasis in mice. *J Endocrinol* 2010;206:297-306.

19. Stovic-Grujicic S, Stojanovic I, Maismovic-Ivanic D, et al. Macrophage migration inhibitory factor (MIF) is necessary for progression of autoimmune diabetes mellitus. *J Cell Physiol* 2008;215:665-675.

20. Sanchez-Zamora Y, Terrazas LI, Vilches-Flores A, et al. Macrophage migration inhibitory factor is a therapeutic target in treatment of non-insulin-dependent diabetes mellitus. *FASEB J* 2010;24:2583-2590.

21. Hoi NY, Iskander MN, Morand EF. Macrophage migration inhibitory factor: a therapeutic target across inflammatory diseases. *Inflamm Allergy Drug Targets* 2007;6:183-190.

22. David JR. Delayed hypersensitivity in vitro: its mediation by cell-free substances formed by lymphoid cell-antigen interaction. *Proc Natl Acad Sci U S A* 1966;56:72-77.

23. Gregory JL, Morand EF, McKeown SJ, et al. Macrophage migration inhibitory factor induces macrophage recruitment via CC chemokine ligand 2. *J Immunol* 2006;177:8072-8079.

24. Gabrilovich DI. Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours. *Nat Rev Immunol* 2012;12:253-268.

25. Youn JI, Nagaraj S, Collazo M, Gabrilovich DI. Subsets of myeloid-derived suppressor cells in tumor-bearing mice. *J Immunol* 2008;181:5791-5802.

26. Xia S, Sha H, Yang L, Ji Y, Ostrand-Rosenberg S, Qi L. Gr-1+ CD11b+ myeloid-derived suppressor cells suppress inflammation and promote insulin sensitivity in obesity. *J Biol Chem* 2011;286:23591-23599.

27. Dietlin TA, Hofman FM, Lund BT, Gilmore W, Stohlman SA, van der Veen RC. Mycobacteria-induced Gr-1+ subsets from distinct myeloid lineages have opposite effects on T cell expansion. *J Leukoc Biol* 2007;81:1205-1212.

28. Tu SP, Jin H, Shi JD, et al. Curcumin induces the differentiation of myeloid-derived suppressor cells and inhibits their interaction with cancer cells and related tumor growth. *Cancer Prev Res (Phila)* 2012;5:205-215.

29. Bozza M, Satoskar AR, Lin G, et al. Targeted disruption of migration inhibitory factor gene reveals its critical role in sepsis. *J Exp Med* 1999;189:341-346.

30. Lansey MN, Walker NR, Hargett SR, Stevens JR, Keller SR. Deletion of Rab GAP AS160 modifies glucose uptake and GLUT4 translocation in primary skeletal muscles and adipocytes and impairs glucose homeostasis. *Am J Physiol Endocrinol Metab* 2012;303:E1273-E1286.

31. Velikovic NS, Djordjevic A, Vasiljevic A, et al. Tissue-specific regulation of inflammation by macrophage migration inhibitory factor and glucocorticoids in fracture-fed Wistar rats. *Br J Nutr* 2012. DOI: http://dx.doi.org/10.1017/S0007114512005193.

32. Santos LL, Fan H, Hall P, et al. Macrophage migration inhibitory factor regulates neutrophil chemoattractant responses in inflammatory arthritis in mice. *Arthritis Rheum* 2011;63:960-970.

33. O’Rourke RW. Inflammation in obesity-related diseases. *Surgery* 2009;145:255-259.

34. Skark T, Herder C, Kräfi I, Müller-Scholze S, Hauner H, Kolb H. Production and release of macrophage migration inhibitory factor from human adipocytes. *Endocrinology* 2005;146:1006-1011.

35. Hausman DB, DiGirolamo M, Bartness TJ, Hausman GJ, Martin RJ. The biology of white adipocyte proliferation. *Obes Rev* 2001;2:239-254.

36. Morris DL, Singer K, Lumeng CN. Adipose tissue macrophages: phenotypic plasticity and diversity in lean and obese states. *Curr Opin Clin Nutr Metab Care* 2011;14:341-346.

37. Harper JM, Wilkinson JE, Miller RA. Macrophage migration inhibitory factor-knockout mice are long lived and respond to caloric restriction. *FASEB J* 2010;24:2436-2442.

38. Fingerle-Rowson G, Petrenko O, Metz CN, et al. The p53-dependent effects of macrophage migration inhibitory factor revealed by gene targeting. *Proc Natl Acad Sci U S A* 2003;100:9354-9359.